Carolir
2022-08-14

Nice

@StickyRice：
Novavax's COVID-19 shot gets approval for use in teenagers in South Korea Novavax (NASDAQ:NVAX) $Novavax(NVAX)$on Friday said its protein-based COVID-19 vaccine had received an expanded approval in South Korea for use in teenagers aged 12 to 17 years. The U.S. company's partner, SK bioscience, got a post approval change application nod from the Korean Ministry of Food and Drug Safety for the COVID shot, Nuvaxovid, NVAX said in a statement. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said NVAX CEO Stanley Erck. Nuvaxovid had already been given approval for use in teenagers aged 12 through 17 years in India, the European Union, Australia, Thailand and Japan, NVAX said. NVAX stock earlier this week crashed 30% after reporting a sharp Q2 revenue miss and lowering its revenue guidance for the year.
Novavax's COVID-19 shot gets approval for use in teenagers in South Korea Novavax (NASDAQ:NVAX) $Novavax(NVAX)$on Friday said its protein-based COVID-19 vaccine had received an expanded approval in South Korea for use in teenagers aged 12 to 17 years. The U.S. company's partner, SK bioscience, got a post approval change application nod from the Korean Ministry of Food and Drug Safety for the COVID shot, Nuvaxovid, NVAX said in a statement. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said NVAX CEO Stanley Erck. Nuvaxovid had already been given approval for use in teenagers aged 12 through 17 years in India, the European Union, Australia, Thailand and Japan, NVAX said. NVAX stock earlier this week crashed 30% after reporting a sharp Q2 revenue miss and lowering its revenue guidance for the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet